8-K: Regulus Therapeutics Announces Positive Clinical Data and Secures $100 Million Private Placement

Regulus Therapeutics reported positive topline data from its Phase 1b trial for RGLS8429 in ADPKD and completed a $100 million private placement.

Summary

• Regulus Therapeutics announced its financial results for the fourth quarter and year ended December 31, 2023, alongside a corporate update.
• The company reported positive topline data from the second cohort of its Phase 1b MAD study of RGLS8429 for Autosomal Dominant Polycystic Kidney Disease (ADPKD).
• The second cohort of 14 patients were randomized 3:1 to receive either 2 mg/kg of RGLS8429 or placebo every other week for three months.
• RGLS8429 showed greater biological activity at 2 mg/kg based on urinary polycystin levels compared to 1mg/kg and placebo.
• Exploratory imaging results showed that 3 patients with the highest increases in PC1 and PC2 had reductions in height-adjusted total kidney volume (htTKV) greater than 4%.
• Regulus completed enrollment of the third cohort of the MAD study, with top-line data expected in mid-2024.
• The company also held a successful Type D meeting with the FDA to discuss the accelerated approval pathway for RGLS8429.
• Regulus closed an oversubscribed $100 million private placement, which is expected to extend its cash runway into the first half of 2026.
• As of December 31, 2023, Regulus had $23.8 million in cash and cash equivalents.
• Research and development expenses were $5.8 million for the fourth quarter and $21.2 million for the year ended December 31, 2023.
• The net loss was $8.1 million, or $0.40 per share, for the fourth quarter and $30.0 million, or $1.58 per share, for the year ended December 31, 2023.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the promising clinical data, successful capital raise, and clear regulatory pathway. However, the company is still loss-making and has risks associated with drug development.

Positives

• The positive topline data from the second cohort of the Phase 1b MAD study suggests that RGLS8429 is showing promise in treating ADPKD.
• The oversubscribed $100 million private placement provides significant financial stability and extends the cash runway into H1 2026.
• The successful Type D meeting with the FDA indicates a clear path for potential accelerated approval of RGLS8429.
• RGLS8429 was well-tolerated with no safety concerns in the second cohort.
• The company has completed enrollment for the third cohort and is planning to initiate the fourth cohort in Q2 2024.

Negatives

• The company reported a net loss of $8.1 million for the fourth quarter and $30.0 million for the year ended December 31, 2023.
• The company's cash and cash equivalents decreased from $39.16 million at the end of 2022 to $23.8 million at the end of 2023.

Risks

• The approach to drug discovery and development is novel and may not lead to marketable products.
• Preliminary or initial results may not be indicative of future results.
• Preclinical and clinical studies may not be successful.
• There are risks related to regulatory review and approval.
• The company relies on third-party collaborators and other third parties.
• There are risks related to intellectual property.
• The company needs additional capital.

Future Outlook

The company expects to share top-line data from the third cohort in mid-2024 and initiate the fourth cohort of the MAD study in Q2 2024. The $100 million private placement is expected to extend the cash runway into the first half of 2026.

Management Comments

• Jay Hagan, CEO of Regulus, stated that they saw evidence of a mechanistic dose response at a 2 mg/kg dose level based on urinary polycystin levels and their potential correlation with improvements in kidney volume and function.
• Jay Hagan also mentioned that the company completed an oversubscribed $100 million private placement due to the strong data and ongoing support of shareholders.

Industry Context

This announcement is significant in the biopharmaceutical industry, particularly for companies focused on rare diseases like ADPKD. The positive clinical data and successful private placement position Regulus as a notable player in the development of microRNA-targeted therapies.

Comparison to Industry Standards

• The accelerated approval pathway discussed with the FDA is similar to that used for other ADPKD treatments, such as Tolvaptan, which was approved based on a reduction in TKV growth.
• The Phase 1b MAD study design, including the use of placebo controls and multiple dose levels, is consistent with industry standards for early-stage clinical trials.
• The reported reductions in htTKV are comparable to results seen in other clinical trials for ADPKD treatments, although direct comparisons are difficult due to differences in study design and patient populations.
• The $100 million private placement is a substantial amount of funding for a company of Regulus' size, indicating strong investor confidence in the company's technology and pipeline.

Stakeholder Impact

• Shareholders will benefit from the extended cash runway and positive clinical data.
• Patients with ADPKD may benefit from the development of a new treatment option.
• Employees may benefit from the company's financial stability and growth prospects.

Next Steps

• The company will share top-line data from the third cohort of the Phase 1b MAD study in mid-2024.
• The company plans to initiate the fourth cohort of the MAD study in Q2 2024.
• The company will amend the protocol to increase the sample size to up to 30 patients in cohort 4.

Key Dates

Keywords

RGLS8429, ADPKD, Autosomal Dominant Polycystic Kidney Disease, microRNA, clinical trial, FDA, private placement, biopharmaceutical, oligonucleotide, Phase 1b, accelerated approval